**Form 1: - Consultant Copy** Telephone Number: Fax Number: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011"

Transcription

1 Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both the Consultant initiating the therapy and the GP who is continuing care. A copy of the completed form should be retained by the GP and a copy should be returned to the Consultant, for filing in the patient s notes. Patient Name: Date of Birth: **Form 1: - Consultant Copy** NHS Number: Patients (Or attach Addressograph label) And / or on behalf of the patient Carer s Name: Careers Consultant Name: Directorate: Fax Number: GP Name: Fax Number: 1 of 7

2 Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both the Consultant initiating the therapy and the GP who is continuing care. A copy of the completed form should be retained by the GP and a copy should be returned to the Consultant, for filing in the patient s notes. Patient Name: Date of Birth: **Form 2: - GP Copy** NHS Number: Patients (Or attach Addressograph label) And / or on behalf of the patient Carer s Name: Careers Consultant Name: Directorate: Fax Number: GP Name: Fax Number: 2 of 7

3 Effective Shared Care Agreement for the treatment of: - Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) This shared care agreement outlines the ways in which the responsibilities for managing the prescribing of cholinesterase inhibitors for dementia in Alzheimer s disease will be shared between the specialist and general practitioner (GP). If the GP is not confident to undertake these roles, then he or she is under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition will remain with the specialist. If a specialist asks the GP to prescribe this drug, the GP should reply to this request as soon as practical. Sharing of care assumes communication between the specialist, GP and patient / carer. The intention to share care should be explained to the patient / carer by the doctor initiating treatment. It is important that patients / carers are consulted about treatment and are in agreement with it. Patients with Alzheimer s dementia are usually under regular specialist follow-up, which provides an opportunity to discuss drug therapy. The doctor who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use. This shared care protocol is drawn from NICE Technology Appraisals TA217 Issued: March 2011 Summary Donepezil, Galantamine and Rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer s disease. Memantine is now recommended as an option for managing moderate Alzheimer s disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer s disease. Author Dr Bernard Udeze Pharmacist: Claire Ault Date of issue: July of 7

4 RESPONSIBILITIES and ROLES Specialist responsibilities Initiation 1 Confirm diagnosis of Alzheimer s dementia. 2 Perform initial assessments. 3 Initiate treatment in accordance with NICE guidance, bearing in mind that the MMSE score should not be relied upon solely in circumstances where it would be inappropriate to do so (for example learning or other disabilities, linguistic or other communication difficulties, where it is not possible to apply the MMSE in a language in which the patient is sufficiently fluent) 4 Seek carer s views on the patient s condition at baseline. 5 Discuss benefits and side effects of treatment with patient and/or carer. 6 Inform patient and carer of the terms under which treatment will be discontinued. 7 Assess likelihood of compliance. 8 Prescribe medication until care is transferred to GP. 9 Ask the GP whether he or she is willing to participate in shared care and explain the intention to share care with the patient and carer. First follow-up assessment within two months and six-monthly assessments 10 Conduct appropriate assessment tests on cognition, BPSD, tolerability and make decision whether to continue treatment or change to an alternative in accordance with NICE guidance. 11 If treatment with cholinesterase inhibitor is not appropriate, manage change of treatment in accordance with NICE guidance and communicate the decision to the patient, carer and GP. Determine and discuss ongoing care needs. 12 If appropriate to continue treatment, titrate the dose if necessary and establish patient on a stable / effective dose. 13 Seek carer s views on the patient s condition at follow-up. 14 Check for side effects and report adverse events to the CSM. Support to GP 15 Provide copy of effective shared care agreement and supporting information. 16 Promptly communicate assessment reports, advising GP of any dosage adjustments required, when to refer back, and when and how to stop treatment. 17 Ensure clear backup arrangements exist for GP for advice and support General Practitioner responsibilities 1 Reply to the request for shared care as soon as practical. 2 Maintenance prescribing, as directed by the specialist. 3 Monitor patients response to treatment; make dosage adjustments if agreed with specialist 4 Monitor compliance 5 Check for possible drug interactions when newly prescribing medication and avoid prescribing interacting drugs. 6 Report to and seek advice from the specialist on any aspect of patient care that is of concern to the GP and may affect treatment 7 Refer back to specialist if condition deteriorates 8 Report any suspected adverse events to specialist team and any severe adverse events to CSM 9 Stop treatment on advice of specialist Patient's / Carer s role 1 Take / administer medication according to doctors instructions. 2 Attend assessments and other appointments. 3 Report to the specialist or GP if he or she does not have a clear understanding of the treatment. 4 Share any concerns in relation to treatment or patient s condition. 5 Report any adverse effects to the specialist or GP. 4 of 7

5 SUPPORTING INFORMATION FOR DONEPEZIL (ARICEPT ) EFFECTIVE SHARED CARE AGREEMENT This information should be read in conjunction with the Summary of Product Characteristics for Donepezil (Aricept ) available from Licensed indications Symptomatic treatment of mild to moderately severe Alzheimer s dementia. Dosage and Administration Initially 5mg once daily at bedtime, increased if necessary after one month to maximum 10mg daily. The orodispersible tablets (Aricept Evess ) should be placed on the tongue, allowed to disperse, and swallowed. Contraindications Patients with a known hypersensitivity to donepezil hydrochloride, piperidine derivatives or to any excipients used in the formulation, including lactose. Precautions for Use Cholinesterase inhibitors may have vagotonic effects on heart rate (e.g., bradycardia). The potential for this action may be particularly important to patients with "sick sinus syndrome" or other supraventricular cardiac conduction conditions, such as sinoatrial or atrioventricular block. Because of their cholinomimetic actions, cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease. Therapeutic Use Refer to NICE technology appraisal guidance 111 (issued March 2011) Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer s disease, available from Monitoring Weight monitoring. MMSE score in accordance with the latest NICE guidance. Side Effects Very common (>1/10): diarrhoea, nausea, headache Common (>1/100, <1/10): common cold, anorexia, hallucinations**, agitation**, aggressive behaviour**, syncope*, dizziness, insomnia, vomiting, abdominal disturbance, rash, pruritis, muscle cramps, urinary incontinence, fatigue, pain 5 of 7

6 Uncommon (>1/1000, <1/100): seizure*, bradycardia, gastrointestinal haemorrhage, gastric and duodenal ulcers, minor increase in serum concentration of muscle creatine kinase Rare (>1/10,000, <1/1000): extrapyramidal symptoms, sino-atrial block, atrioventricular block, liver dysfunction including hepatitis*** * In investigating patients for syncope or seizure, the possibility of heart block or long sinusal pauses should be considered. ** Reports of hallucinations, agitation and aggressive behaviour have resolved on dose-reduction or discontinuation of treatment. *** In cases of unexplained liver dysfunction, withdrawal of donepezil should be considered. The ability of Alzheimer s patients on donepezil to continue driving or operating complex machinery should be routinely evaluated. Drug Interactions Donepezil may increase the neurotoxic effect of antipsychotics. Metabolism is via cytochrome P450 enzymes 3A4 and 2D6. Metabolism may be inhibited (levels increased) by ketoconazole, quinidine, itraconazole, erythromycin, cimetidine, paroxetine and fluoxetine. Metabolism may be increased (levels reduced) by rifampicin, carbamazepine, phenytoin and alcohol. Donepezil may increase the neuromuscular-blocking effect of succinylcholine and may increase the adverse effects of cholinergic agonists. It may also increase the bradycardic effect of beta-blockers, diltiazem, verapamil, digoxin and amiodarone. Donepezil may antagonise the effect of anti-cholinergic medications. Primary Care Costs (BNF March 2011) Aricept 5mg / 28 tablets 10mg / 28 tablets References Date of access 30/6/2011 British National Formulary No 61 (March 2011). BMJ and Pharmaceutical Press: London. NICE. TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: guidance (March 2011). Accessed via Aricept Summary of Product Characteristics. Eisai Ltd. Last updated 27/07/ /07/11 Accessed Aricept Evess Summary of Product Characteristics. Eisai Ltd. Last updated 27/07/2010. Accessed 14/07/11. 6 of 7

7 BACK-UP ADVICE AND SUPPORT Contact details Specialist: Telephone No. Bleep: Fax: address: GP: Hospital Medicines Information Dept: uhns.nhs.uk Other: 7 of 7

Guidance on initiating the Prescribing of Donepezil in Primary Care

Guidance on initiating the Prescribing of Donepezil in Primary Care Guidance on initiating the Prescribing of Donepezil in Primary Care 1st edi(on, September 2013 Introduction This guidance has been commissioned by the Strategic Clinical Network for Mental Health, Dementia,

More information

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )

Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR

More information

N-methyl-D-aspartate (NMDA) Receptor Antagonist Memantine (CWM TAF ONLY)

N-methyl-D-aspartate (NMDA) Receptor Antagonist Memantine (CWM TAF ONLY) Bro Taf Localities Drugs & Therapeutics Committee SHARED CARE Drugs: Acetylcholinesterase inhibitors - Donepezil, Rivastigmine and Galantamine (Cardiff and Vale and Cwm Taf) Protocol No. CV 52 N-methyl-D-aspartate

More information

Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD)

Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) SHARED CARE PROTOCOL AND INFORMATION FOR GPS Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) Version: 3 Date Approved: June 2011 Review

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E040 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1.

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: The prescribing and monitoring of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer s Disease. Scope: Pennine Care NHS Foundation Trust NHS

More information

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James

More information

Prescribing Framework for Donepezil in the Treatment and Management of Dementia

Prescribing Framework for Donepezil in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP

More information

Information for Prescribing Anti-dementia Drugs. November 2012

Information for Prescribing Anti-dementia Drugs. November 2012 Information for Prescribing Anti-dementia Drugs The aim of this document is to provide information about the prescribing of anti-dementia medication for adult patients with dementia following an assessment

More information

Shared care protocol for the prescribing and monitoring of Donepezil, Rivastigmine, Galantamine and Memantine in accordance with NICE TA217

Shared care protocol for the prescribing and monitoring of Donepezil, Rivastigmine, Galantamine and Memantine in accordance with NICE TA217 Shared care protocol for the prescribing and monitoring of Donepezil, Rivastigmine, Galantamine and Memantine in accordance with NICE TA217 PATIENT S NAME: PATIENT S ADDRESS: HOSPITAL NAME AND NHS NUMBER

More information

Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease

Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease IS 11 October 2011 Information sheet Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease Introduction... 1 How does Aricept work?... 1 Who might benefit from Aricept?... 2 What effect

More information

Integrated Medication Guidelines for. Use of Donepezil, Galantamine, Rivastigmine and Memantine in Alzheimer s Disease

Integrated Medication Guidelines for. Use of Donepezil, Galantamine, Rivastigmine and Memantine in Alzheimer s Disease Integrated Medication Guidelines for Use of Donepezil, Galantamine, Rivastigmine and Memantine in Alzheimer s Disease Objectives: Safe prescribing in dementia Innovative thinking in dementia prescribing

More information

NHS ONEL and NELFT Shared Care Guidelines. Management of medications for Alzheimer s disease. Patient Name : Date of Birth: NHS No:

NHS ONEL and NELFT Shared Care Guidelines. Management of medications for Alzheimer s disease. Patient Name : Date of Birth: NHS No: NHS ONEL and NELFT Shared Care Guidelines Management of medications for Alzheimer s disease DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name

More information

Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease

Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease 1. REFERRAL CRITERIA Patients of any age that are suspected to be suffering from moderate to severe Alzheimer s disease will

More information

Package leaflet: Information for the patient. Donecept 5 mg film-coated tablets Donecept 10 mg film-coated tablets. Donepezil hydrochloride

Package leaflet: Information for the patient. Donecept 5 mg film-coated tablets Donecept 10 mg film-coated tablets. Donepezil hydrochloride Package leaflet: Information for the patient Donecept 5 mg film-coated tablets Donecept 10 mg film-coated tablets Donepezil hydrochloride Read all of this leaflet carefully before you start taking this

More information

SHARED CARE GUIDELINE FOR TREATMENT OF DEMENTIA 1. Aim/Purpose of this Guideline

SHARED CARE GUIDELINE FOR TREATMENT OF DEMENTIA 1. Aim/Purpose of this Guideline SHARED CARE GUIDELINE FOR TREATMENT OF DEMENTIA 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration

More information

Memantine (Ebixa) Drug treatment for Alzheimer s disease

Memantine (Ebixa) Drug treatment for Alzheimer s disease IS 20 October 2011 Information sheet Memantine (Ebixa) Drug treatment for Alzheimer s disease Introduction... 1 How does Ebixa work?... 1 Who might benefit?... 2 What effect might Ebixa have?... 2 How

More information

Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.

Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written

More information

Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease

Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease IS 17 October 2011 Information sheet Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease Introduction... 1 How does Reminyl work?... 1 Who might benefit?... 2 What effect might Reminyl

More information

Dementa Formulary Guidance [v1.0]

Dementa Formulary Guidance [v1.0] Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more

More information

Transfer of Care Guidelines: Management of Dementia Drugs Process Summary

Transfer of Care Guidelines: Management of Dementia Drugs Process Summary Transfer of Care Guidelines: Management of Dementia Drugs Process Summary Following assessment under EMDASS, patient is diagnosed with mild to severe Alzheimer s disease and is suitable for treatment with

More information

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEMENTIA Pharmacological Treatment of Alzheimer s disease The three acetylcholinesterase (AChE) inhibitors (donepezil,

More information

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within

More information

Each film-coated tablet contains 5 mg or 10 mg donepezil hydrochloride.

Each film-coated tablet contains 5 mg or 10 mg donepezil hydrochloride. 1. NAME OF THE MEDICINAL PRODUCT Donecept 5 mg film-coated tablets Donecept 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg or 10 mg donepezil

More information

U.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc.

U.S. Scientific Update Aricept 23 mg Tablets. Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. U.S. Scientific Update Aricept 23 mg Tablets Dr. Lynn Kramer President NeuroScience Product Creation Unit Eisai Inc. Unmet Need in Moderate to Severe Alzheimer s Disease (AD) Ongoing clinical deterioration

More information

www.bpac.org.nz keyword: donepezil The pharmacological management of Alzheimer s disease: The place of donepezil 28 BPJ Issue 30

www.bpac.org.nz keyword: donepezil The pharmacological management of Alzheimer s disease: The place of donepezil 28 BPJ Issue 30 www.bpac.org.nz keyword: donepezil The pharmacological management of Alzheimer s disease: The place of donepezil 28 BPJ Issue 30 Donepezil to be funded for the treatment of Alzheimer s disease As the world

More information

Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease

Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease Understanding NICE guidance Information for people who use NHS services Donepezil, galantamine, rivastigmine and memantine for Alzheimer s disease NICE technology appraisal guidance advises on when and

More information

Bisoprolol in the Treatment of Heart Failure

Bisoprolol in the Treatment of Heart Failure Heart Failure Prescribing Guidelines Beta-Blocker Dose Titration Schedule Appendix 2A in the Treatment of Heart Failure Applicable to: All patients diagnosed with and commenced on bisoprolol. Patients

More information

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Issue date: November 2006 (amended September 2007, August 2009) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a review of NICE

More information

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217

Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2011. All rights reserved.

More information

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour. Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,

More information

Medication for Dementia (Acetylcholinesterase Inhibitors)

Medication for Dementia (Acetylcholinesterase Inhibitors) Older People s Mental Health Service Medication for Dementia (Acetylcholinesterase Inhibitors) August 2011 ^ ãéãäéê çñ `~ãäêáçöé råáîéêëáíó eé~äíü m~êíåéêë What are they? A group of medications used to

More information

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf

More information

Pharmacotherapy of BPSD. Pharmacological interventions. Anti-dementia drugs. Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence

Pharmacotherapy of BPSD. Pharmacological interventions. Anti-dementia drugs. Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence Pharmacotherapy of BPSD Abhilash K. Desai MD Medical Director Alzheimer s Center of Excellence Pharmacological interventions Reducing medication errors. Reducing potentially inappropriate medication prescription.

More information

Normal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006

Normal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006 Normal Aging versus Alzheimer Disease Drugs to treat the symptoms that are not due to old age. Leah Wright, HBSc. BSP student June 2006 Alzheimer Disease is a form of dementia that affects 5% of men and

More information

LEFLUNOMIDE (Adults)

LEFLUNOMIDE (Adults) Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active

More information

CONTINUING CARE GUIDELINES AND INFORMATION FOR NEP STAFF AND GENERAL PRACTITIONERS IN NORTH ESSEX

CONTINUING CARE GUIDELINES AND INFORMATION FOR NEP STAFF AND GENERAL PRACTITIONERS IN NORTH ESSEX NORTH ESSEX PARTNERSHIP UNIVERSITY NHS FOUNDATION TRUST POLICY DOCUMENT MEDICINES GUIDANCE CONTINUING CARE Document Title Acetylcholinesterase (AChI) inhibitors and memantine prescribing and treatment

More information

Maintenance of abstinence in alcohol dependence

Maintenance of abstinence in alcohol dependence Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly

More information

GMMMG Interface Prescribing Subgroup. Shared Care Template

GMMMG Interface Prescribing Subgroup. Shared Care Template GMMMG Interface Prescribing Subgroup Shared Care Template Shared Care Guideline for Selective Serotonin Reuptake Inhibitors (SSRIs) for the treatment of Obsessive Compulsive Disorder (OCD) and Body Dysmorphic

More information

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

Carvedilol in the Treatment of Heart Failure

Carvedilol in the Treatment of Heart Failure Appendix 2B Heart Failure Prescribing Guidelines Rotherham PCT Applicable to: Carvedilol in the Treatment of Heart Failure All patients diagnosed with and commenced on carvedilol. Patients not discharged

More information

Homma A, Imai Y, Tago H, Asada T, et al. Dement Geriatr Cogn Disord. 2009;27(3):232-9. Epub 2009 Feb 25.

Homma A, Imai Y, Tago H, Asada T, et al. Dement Geriatr Cogn Disord. 2009;27(3):232-9. Epub 2009 Feb 25. ALZIL (Donepezil) Available as tablets: 5 mg, 10 mg (1) Indications (for elderly): symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer s type (2) Recent trials: Abstract

More information

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK ACAMPROSATE CALCIUM (Campral EC) for alcohol abstinence ESCA: Adjunct in the treatment of chronic alcohol dependence (under

More information

To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at 1-888-274-2378 (fax 1-201-746-3207) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at 1-888-274-2378 (fax 1-201-746-3207) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ARICEPT safely and effectively. See full prescribing information for ARICEPT. ARICEPT (donepezil

More information

Teriflunomide (Aubagio) 14mg once daily tablet

Teriflunomide (Aubagio) 14mg once daily tablet Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision

More information

Long Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)

Long Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine) 1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s

More information

Document name: Portfolio Document type: Staff group to whom it applies: Distribution: How to access: Issue date: Next review: Approved by:

Document name: Portfolio Document type: Staff group to whom it applies: Distribution: How to access: Issue date: Next review: Approved by: Document name: Focus on paroxetine Portfolio Document type: Medicines Management Communication Staff group to whom it applies: All prescribers, pharmacy and clinical staff within the Trust Distribution:

More information

Clinical Audit: Prescribing antipsychotic medication for people with dementia

Clinical Audit: Prescribing antipsychotic medication for people with dementia Clinical Audit: Prescribing antipsychotic medication for people with dementia Trust, team and patient information Q1. Patient's DIS number... Q2. Patient s residence: Home Residential Home Nursing Home

More information

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma

More information

Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment

Objectives. Aging and Forgetfulness Define Dementia Types of Dementia Treatment Dementia David Lam, MD, FRCPC, Psychiatry Assistant Clinical Professor Department of Psychiatry and Behavioural Neurosciences McMaster University Hamilton, Ontario Objectives Aging and Forgetfulness Define

More information

Emergency Room Treatment of Psychosis

Emergency Room Treatment of Psychosis OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different

More information

VALIUM PRODUCT MONOGRAPH. diazepam. 5 mg Tablets. Anxiolytic-sedative. Date of Revision: February 7, 2014

VALIUM PRODUCT MONOGRAPH. diazepam. 5 mg Tablets. Anxiolytic-sedative. Date of Revision: February 7, 2014 PRODUCT MONOGRAPH VALIUM diazepam 5 mg Tablets Anxiolytic-sedative Hoffmann-La Roche Ltd. 7070 Mississauga Road Mississauga, Ontario L5N 5M8 Date of Revision: February 7, 2014 www.rochecanada.com Submission

More information

What is Alzheimer s disease?

What is Alzheimer s disease? What is Alzheimer s disease? Contents Introduction 03 What is Alzheimer s? 04 Symptoms 06 Diagnosis 08 Support 14 Causes 15 Risk factors 16 Research 19 Treatments 10 02 visit: www.alzheimersresearchuk.org

More information

New Zealand Data Sheet

New Zealand Data Sheet MESTINON Pyridostigmine bromide Presentation New Zealand Data Sheet 60mg tablet: round, flat-faced, white tablets engraved "Mestinon 60" on outer perimeter and "V" in the centre, with a quadrisect score

More information

Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists

Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Traffic light classification- Amber 2 specialist initiation Information sheet for Primary Care Prescribers

More information

COMPASS Therapeutic Notes on the Management of Dementia

COMPASS Therapeutic Notes on the Management of Dementia COMPASS Therapeutic Notes on the Management of Dementia In this issue Introduction: Background Symptoms & Diagnosis Page Prevention Strategies 6 Management of Cognitive Symptoms of Dementia Management

More information

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment

Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Kinga Szigeti, MD Associate Professor UBMD Neurology UB Department of Neurology Questions How do we differentiate

More information

Dementia. Your medicine. Information for you. Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa

Dementia. Your medicine. Information for you. Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Dementia Your medicine Information for you Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available in other formats

More information

Barbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. Junior Editor: Karen L.A. Wlock, B.Sc.(Pharm.) - Memantine This edition edited by: B.

Barbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. Junior Editor: Karen L.A. Wlock, B.Sc.(Pharm.) - Memantine This edition edited by: B. Volume 28 (1) 2008 Senior Editor: Contents Barbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. - Dementia Therapy Junior Editor: Karen L.A. Wlock, B.Sc.(Pharm.) - Memantine This edition edited by: B. Cadario

More information

These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.

These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical

More information

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW

Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia

More information

Ulipristal (Esmya ) 5mg tablets for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women.

Ulipristal (Esmya ) 5mg tablets for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women. May 2016 Ulipristal (Esmya ) 5mg tablets for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women. The New Therapies Subgroup discussed the above at its meeting

More information

Update on Treatment of the Dementias

Update on Treatment of the Dementias Update on Treatment of the Dementias Mark Pippenger, MD Behavioral Neurology Associate Clinical Professor of Neurology University of Arkansas for Medical Sciences Disclosures I will be discussing off-label

More information

A New Combinational Therapy in the Treatment of Alzheimer s Disease

A New Combinational Therapy in the Treatment of Alzheimer s Disease online at www.ijpcr.com International Journal of Pharmaceutical and Clinical Research 2015; 7(5): 337-342 Research Article ISSN- 0975 1556 A New Combinational Therapy in the Treatment of Alzheimer s Disease

More information

Alzheimer Disease Pharmacologic Treatment and Treatment Research Lon S. Schneider, MD, MS

Alzheimer Disease Pharmacologic Treatment and Treatment Research Lon S. Schneider, MD, MS Review Article Alzheimer Disease Pharmacologic Treatment and Treatment Research Lon S. Schneider, MD, MS ABSTRACT Purpose of Review: This article reviews marketed pharmacologic treatments for Alzheimer

More information

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep

More information

patient group direction

patient group direction DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner

More information

White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other.

White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. Nausicalm Cyclizine hydrochloride Ph. Eur. 50 mg Presentation White, circular, biconvex, uncoated tablets with a score line on one side, plain on the other. Uses Actions The active ingredient-cyclizine

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

Package Leaflet: Information for the Patient

Package Leaflet: Information for the Patient Package Leaflet: Information for the Patient TERBINAFINE 250mg TABLETS Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this

More information

ZOPICLONE Page 34 of 38

ZOPICLONE Page 34 of 38 PART III: CONSUMER INFORMATION Pr ZOPICLONE zopiclone tablets This leaflet is part III of a three-part "Product Monograph" published when ZOPICLONE was approved for sale in Canada and is designed specifically

More information

Long-term benefits of galantamine (Reminyl ) in Alzheimer s disease. Michael Gold 1, Sean Lilienfeld 2, & Luc Truyen 1

Long-term benefits of galantamine (Reminyl ) in Alzheimer s disease. Michael Gold 1, Sean Lilienfeld 2, & Luc Truyen 1 Long-term benefits of galantamine (Reminyl ) in Alzheimer s disease Michael Gold 1, Sean Lilienfeld 2, & Luc Truyen 1 1 Johnson & Johnson Pharmaceutical Research and Development, Titusville, New Jersey

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

NCCP Chemotherapy Protocol. Afatinib Monotherapy

NCCP Chemotherapy Protocol. Afatinib Monotherapy Afatinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

More information

BNSSG Health Community s Traffic Light System Shared Care Guidance

BNSSG Health Community s Traffic Light System Shared Care Guidance NHS Bristol NHS North Somerset NHS South Gloucestershire North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Health Community s Traffic Light System

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Omeprazol XXX 40 mg powder for solution for infusion omeprazole

PACKAGE LEAFLET: INFORMATION FOR THE USER Omeprazol XXX 40 mg powder for solution for infusion omeprazole PACKAGE LEAFLET: INFORMATION FOR THE USER Omeprazol XXX 40 mg powder for solution for infusion omeprazole Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You

More information

SIDE EFFECTS OF APPROVED ANTIDEMENTIVES

SIDE EFFECTS OF APPROVED ANTIDEMENTIVES Medicinska naklada - Zagreb, Croatia Conference paper SIDE EFFECTS OF APPROVED ANTIDEMENTIVES Ninoslav Mimica 1,2 & Paola Presečki 3 1 Psychiatric Hospital Vrapče, Bolnička cesta 32, HR-10090 Zagreb, Croatia

More information

An Evidence-based Critical Appraisal of a Topic: Effectiveness of High Dose Donepezil for Advanced Alzheimer s Disease

An Evidence-based Critical Appraisal of a Topic: Effectiveness of High Dose Donepezil for Advanced Alzheimer s Disease ORIGINAL RESEARCH An Evidence-based Critical Appraisal of a Topic: Effectiveness of High Dose Donepezil for Advanced Alzheimer s Disease Charlene R. Hoffman Snyder, DNP, FNP-BC, and Lynda Facchiano, DNP,

More information

Stowe School Medications Policy

Stowe School Medications Policy INTRODUCTION Most pupils will need medication at some stage of their school life. Although this will mainly be for short periods there are a few pupils with chronic conditions who may require regular medication

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 4.9: Drugs Used in Parkinsonism and related Disorders Co-Beneldopa 12.5/50, 25/100 and 50/200 (Madopar) Capsules Co-Beneldopa 12.5/50 and 25/100 Dispersible

More information

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics

More information

Alcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice

Alcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice Dr IM Joubert Alcohol and nicotine are widely abused substances and are often used together One study showed that 15% of patients visiting a primary care practice for any reason had either an at-risk pattern

More information

This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.

This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative. This document can be made available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on 01224 551116 or 01224 552245. This controlled document

More information

Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement

Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement A Copy of this page signed by all three parties should be retained in the

More information

What Codeine Phosphate Tablets are used for

What Codeine Phosphate Tablets are used for New Zealand Consumer Medicine Information CODEINE PHOSPHATE 15mg, 30mg & 60mg Tablets What is in this leaflet Please read this leaflet carefully before you start using Codeine Phosphate Tablets. This leaflet

More information

Valoid 50 mg Tablets (cyclizine hydrochloride)

Valoid 50 mg Tablets (cyclizine hydrochloride) IRL 075-3236-APIL 28032354 Package leaflet: Information for the patient Valoid 50 mg Tablets (cyclizine hydrochloride) Read all of this leaflet carefully before you start taking this medicine because it

More information

Berkshire West CCGs Alcohol Treatment Pathway for Nalmefene (Selincro) Primary Care Guidance

Berkshire West CCGs Alcohol Treatment Pathway for Nalmefene (Selincro) Primary Care Guidance Berkshire West CCGs Alcohol Treatment Pathway for Nalmefene (Selincro) Primary Care Guidance Nalmefene (trade name Selincro) was given approval by NICE in November 2014 and should be available to use with

More information

Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets

Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Read this Patient Information carefully before you start taking VYTORIN and each time you get a refill. There may be new information.

More information

Prescribing antipsychotics to older people: report from pilot study

Prescribing antipsychotics to older people: report from pilot study Prescribing antipsychotics to older people: report from pilot study Prepared by Rebecca Harris, bpac nz for PHARMAC September, 2015 bpac nz Prescribing antipsychotics to older people: Report from pilot

More information

Review of Pharmacological Pain Management

Review of Pharmacological Pain Management Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization

More information

Guidelines for Dementia Syndrome

Guidelines for Dementia Syndrome Guidelines for Dementia Syndrome Dementia is the chronic acquired decline in memory and at least one other cognitive function (e.g. language, visual-spatial, executive) sufficient to offset daily life.

More information

PATIENT GROUP DIRECTION (PGD) ADMINISTRATION OF INHALED SALBUTAMOL FOR THE EMERGENCY TREATMENT OF ACUTE ASTHMA OR COPD EXACERBATION AT HMP FORD

PATIENT GROUP DIRECTION (PGD) ADMINISTRATION OF INHALED SALBUTAMOL FOR THE EMERGENCY TREATMENT OF ACUTE ASTHMA OR COPD EXACERBATION AT HMP FORD PATIENT GROUP DIRECTION (PGD) ADMINISTRATION OF INHALED SALBUTAMOL FOR THE EMERGENCY TREATMENT OF ACUTE ASTHMA OR COPD EXACERBATION AT HMP FORD Version Number: 01HMP Patient Group Direction originally

More information

Shared Care Agreement Insulin Degludec (Tresiba )

Shared Care Agreement Insulin Degludec (Tresiba ) Licensed Indication Shared Care Agreement Insulin Degludec (Tresiba ) Insulin Degludec is licensed for the treatment of diabetes mellitus in adults. Countess of Chester prescribing guidelines Restricting

More information

NHS FORTH VALLEY Thyroid Storm

NHS FORTH VALLEY Thyroid Storm NHS FORTH VALLEY Thyroid Storm Date of First Issue 01 August 2006 Approved 01 August 2006 Current Issue Date 1 st July 2016 Review Date 1 st July 2018 Version EQIA Yes 01/08/2010 Author / Contact Group

More information

MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES

MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES Version control: Version Date Main changes/comments V1 4 June 2013 First draft circulated

More information

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail

Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Indication: Neoadjuvant or adjuvant therapy for elderly and frail patients with breast

More information

From the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care

From the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care From the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care August 2015 Issue Futile Drugs in Hospice Patients Managing medications in hospice patients can be a difficult

More information

Geodon (ziprasidone)

Geodon (ziprasidone) Geodon (ziprasidone) FDA ALERT [04/2005] Geodon is a type of medicine called an atypical antipsychotic. FDA has found that older patients treated with atypical antipsychotics for dementia had a higher

More information